Диссертация (1140690), страница 27
Текст из файла (страница 27)
175183.189.Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health andNutrition Examination Survey / D. Martins [et al.] // Actives of Internal Medicine. –2007. – Vol. 167, № 11. – P. 1159-1165.190.Prevention and treatment of glucocorticoid–induced osteoporosis withactive vitamin D3 analogues: a review with meta–analysis of randomized controlledtrials including organ transplantation studies / R. Nijs [et al.] // Osteoporosis Int.
– 2004.– Vol. 15. – P. 589-682.191.Prevention, clinical, and pathophyziological research in vibration syndrome/ S. Yamada [et al] // Nagoya J. Med. Sci. – 2003. – Vol. 56, № l-4. – P. 27-41.192.Prevention of osteoporosis and uterine effects in postmenopausal womentaking raloxifene for 5 years / E. E. Jolly [et al.] // Menopause. – 2003.
– Vol. 10, № 4.– P. 337-344.193.Prevention of postmenopausal bone loss by pulsed estrogen therapy:comparison with transdermal route / P. D. Delmas [et al.] // Maturitas. – 2004. – Vol.48, № 2. – P. 85-96.194.Price, P. A. 1.25-Dihydroxyvitamin D3 increases synthesis of the vitamin-K dependent bone protein by osteosarcoma cells / P. A.
Price, S. A. Baucol // J. Biol.Chem. – 1980. – № 255. – P. 11660-11663.195.Raloxifene and cardiovascular events in osteoporotic postmenopausalwomen: four-year results from the MORE (Multiple Outcomes of RaloxifeneEvaluation) randomized trial // E. Barrett-Connor [et al.] // JAMA. – 2002. – Vol. 287,№ 7.
– P. 847-857.167196.Ralston, S. H. Estrogen inhibits release of tumor necrosis factor fromperipheral blood mononuclear cells in postmenopausal women / S. H. Ralston, R. G. G.Russell, M. Gowen // J. Bone Mener. Res. – 1990. – № 5. – P. 983-988.197.Recker, R. The effect of anti resorption on bone quality / R.
Recker, L.Armas // Clin. Orthop. Relat. Res. – 2011. – Vol. 469. – P. 2207-2214.198.Recker, R. R. Current therapy for osteoporosis / R. R. Recker // J. Clin.Endocrinol. Metab. – 1993. – Vol. 76. – P. 14-16.199.Reduction of vertebral fracture risk in postmenopausal women withosteoporosis treated with raloxifene: results from a 3-year randomized clinical trial / B.Ettinger [et al.] // JAMA. – 1999. – Vol. 282, № 7.
– P. 637-645.200.Response rates to oestrogen treatment in perimenopausal women: 5-yeardata from the Danish Osteoporosis Prevention Study (DOPS) / T. Rejnmark [et al.] //Matoritas. – 2004. – Vol. 48, № 3. – P. 307-320.201.Results of indirect and mixed treatment comparison of fracture efficacy forosteoporosis treatments: a meta-analysis / N. Freemantle [et al.] // Osteoporos Int. –2013.
– Vol. 24, № 1. – P. 209-217.202.Risks and benefits of estrogen plus progestin in healthy postmenopausalwomen: principal results from the Women’s Health Initiative randomized controlledtrial / J. E. Rossouw [et al.] // J. Am. Med. Assoc. – 2002. – Vol. 288, № 3.
– P. 321323.203.Rogers, M. J. New insights into the molecular mechanisms of action ofbisphospnonates 7 / M. J. Rogers // Curr. Pharm. Des. – 2003. – № 9. – P. 2643-2658.204.Role of RANKL ligand in mediating increased bone resorption in earlypostmenopausal women / G. Eghbali-Fatourechi [et al.] // J. Clin Invest.
– 2003. – №111. – P. 1221-1230.205.Roodman, G. Role of cytokines in the regulation of bone resorption / G.Roodman // Calcif. Tiss. Int. – 1993. – Vol. 53, suppl. 1. – P. 94-98.206.Rowe, D. W. Regulation of collagen synthesis in fetal rat calvaria by 1.25-dihydroxyvitamin D3 / D. W. Rowe, B. E. Kream // J.
Biol. Chem. – 1982. – № 257. –P. 8009-8015.168207.Sakakibara, H. Thermotactile threshold testing for the evaluation of sensorynerve function in vibration-exposed patients and workers / H. Sakakibara, S. Maeda, Y.Yonekawa // Int. Arch. Occup. Environ.
Health. – 2002. – Vol. 75, № 1/2. – P. 90-96.208.Sakakura, M. Inhibition of luteinizing hormone secretion induced bysynthetic LRH bylong-term treatment with glucocorticoids in human subjects / M.Sakakura, K. Takebe, S. Nakagawa // J. Clin Endocrinol. Metab. – 1975. – № 40. – P.774-776.209.Schneeweis, L.
A. Functional dissociation of osteoprotogerin and itsinteraction with receptor activator of NF-kB ligand / L. A. Schneeweis, D. Willard, M.E. Milla // J. Biol. Chem. – 2005. – № 280, suppl. 41. – P. 155-164.210.Scragg, R. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in theThird National Health and Nutrition Examination Survey / R. Scragg, M. Soers, C. Bell// Diabetes Care. – 2004.
– Vol. 27, № 12 – P. 2813-2818.211.Skeletal effects of raloxifene after 8 years: results from the continuingoutcomes relevant Relevant to Evista (CORE) study / E. S. Siris [et al.] // J. BoneMiner.Res. – 2005. – Vol. 20, № 9. – P. 1514-1524.212.Stevenson, J. C.
Justification for the use of HRT in the long-termprevention of osteoporosis / J. C. Stevenson // Maturitas. – 2005. – Vol. 51, № 2. – P.113-126.213.Stimulation of osteoprotogerin ligand and inhibition of osteoprotogerinproduction by glucocorticoids in human osteoblastic lineage cells: Potential paracrinemechanisms of glucocorticoids-inducedosteoporosis / L. C. Hofbauer [et al.] //Endocrinology. – 1999.
– № 140. – P. 4382-4389.214.Strontium ranelate effect on proliferation and OPG expression inosteoblasts / T. C. Brennan [et al.] // Calcif. Tissue. – 2006. – № 78. – P. S129.215.Strontium ranelate for preventing and postmenopausal osteoporosis: review/ S. O’Donell [et al.]. – New York : John Wiley & Sons, Ltd., 2008. – 38 p.216.Strontium ranelate improves bone resistance by increasing bone massimproving architecture in intact female rats / P. Ammann [et al.] // J. Bone Miner. Res.– 2004. – Vol. 19, № 12.
– P. 2012-2020.169217.Strontium ranelate promotes chemotaxis, stimulates proliferation andindices gene involved in the differentiation of rat primary osteoblasts / N. Chattopadyay[et al.] // Bone. – 2005. – № 36. – P. S400.218.Strontium ranelate reduces the risk of nonvertebral fractures inpostmenopausal women with osteoporosis treatment of peripheral osteoporosis(TROPOS) study / J.
Y. Reginster [et al.] // J. Clinical Endocrinology and Metabolism.– 2005. – Vol. 90, № 5. – P. 2816-2822.219.Superiority of combined treatment of Alendronate and Alfacalcidolcompared to the combination of Alendronate and plain vitamin D or Alfacalcidol alonein established postmenopausal or male osteoporosis (AAC-Trial) / J. D. Ringe [et al.] //Rheumatol. Int. – 2007. – № 27. – P. 425-434.220.TenYearsExperiencewithAlendronateforOsteoporosisinPostmenopausal Women / H.
G. Bone [et al.] // N. Engl. J. Med. – 2004. – Vol. 350. –P. 1189-1199.221.The effect of 1α(OH)D3 on bone metabolism in parathyroidectomized ratswith continuous PTH infusion / A. Shiraishi [et al.] // Osteoporosis Int. 1997. – № 7,suppl. 2. – P. 35.222.The effects of calcium and vitamin D supplementation on blood glucoseand markers of inflammation in nondiabetic adults / A. G. Pittas [et al.] // DiabetesCare. – 2007. – Vol.
30, № 4. – P. 980-986.223.The effect of dietary patterns on blood pressure control in hypertensivepatients: results from the Dietary Approaches to Stop Hypertension (DASH) trial / P. R.Conlin [et al.] // Am. J. Hypertens. – 2000. – Vol. 13, № 9.
– P. 949-955.224.The effect of teriparatide [human parathyroid hormone (1-34)] therapy onbone density in men with osteoporosis / E. S. Orwoll [et al] // J. Bone Mineral Research.– 2003. – Vol. 18. – P. 9-17.225.Tran, Van P. An electron microscopic study of the bone-remodelingsequence in the rat / Tran Van P., A. Vignery, R. Baron // Cell Tissue Res. – 1982. – №225. – P. 283-292.170226.Tran, Van P. Cellular kinetics of the bone remodeling sequence in the rat /Tran Van P., A. Vignery, R. Baron // Anat. Rec.
– 1982. – № 202. – P. 441-451.227.Vertebral fracture risk reduction with strontium ranelate in women withpostmenopausal osteoporosis is independent of baseline risk factors / C. Roux [et al.] //J. Bone Miner. Res. – 2006. – Vol. 21, № 4. – P. 536-542.228.Vitamin D Analogs Versus Native Vitamin D in Preventing Bone loss andOsteoporosis-Related Fractures: A Comparative Meta-analysis / F. Richy [et al.] //Calcif. Tissue Int. – 2005. – № 76. – P. 176-186.229.Vitamin D and calcium supplementation reduces cancer risk: Results ofrandomized trial / J. M. Lappe [et al.] // Am.
J. Clin. Nutr. – 2007. – Vol. 85, № 6. – P.1586-1591.230.Vitamin D and diabetes / C. Mathieu [et al.] // Diabetologia. – 2005. – Vol.48, № 7. – P. 1247-1257.231.Vitamin D intake and risk of incidence hypertension: results from threelarge prospective cohort studies / J. P. Forman [et al.] // Hypertension. – 2005. – Vol.46, № 4. – P.
676-682.232.Vitamin D. / eds.: D. Feldman, F. H. Glorieux, J. W. Pike. – San Diego :Academic Press, 1997. – 1285 p.233.Wilcoxon F. Individual comparisons by ranking methods // BiometricaBulletin. 1945. Vol. 1. P. 80.234.Wilcoxon F. Probability tables for individual comparisons by rankingmethods // Biometrics. 1947. Vol. 3. P.
119.235.Yoon, K. Tissue specificity and developmental expression of ratosteopontin / K. Yoon, R. Buenaga, G. A. Rodan // Biochem. Biophys. Res. Commun. –1987. – № 147. – P. 1129-1136..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
